Comerica Bank’s Zevra Therapeutics ZVRA Stock Holding History

Comerica Bank’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-165	Closed	-$1.38K	–	3771
2024 Q4	$1.38K	Buy	+165	New	+$1.41K	﹤0.01%	3533

Other funds holding ZVRA

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

ACM

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Comerica Bank's ZVRA Position: Q1 2025 in Review

Comerica Bank sold out of Zevra Therapeutics (ZVRA) in Q1 2025, closing a stake of 165 shares — an estimated $1.38K sold.

Comerica Bank first reported a position in ZVRA in Q4 2024 and held it in 1 quarter. The position peaked at $1.38K in Q4 2024. 110 funds tracked by Wall St. Rank hold ZVRA as of Q1 2025.

Comerica Bank reported no remaining Zevra Therapeutics position as of Q1 2025 after selling out during the quarter.
Comerica Bank sold 165 Zevra Therapeutics shares in Q1 2025, an estimated $1.38K.
Comerica Bank first reported a position in Zevra Therapeutics in Q4 2024 and held it in 1 quarter.
Comerica Bank's Zevra Therapeutics position peaked at $1.38K in Q4 2024.
110 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2025.

Based on Comerica Bank's 13F filing for Q1 2025, filed 14 May 2025.